177 related articles for article (PubMed ID: 23385474)
1. Serum prolactin concentration at presentation of non-functioning pituitary macroadenomas.
Behan LA; O'Sullivan EP; Glynn N; Woods C; Crowley RK; Tun TK; Smith D; Thompson CJ; Agha A
J Endocrinol Invest; 2013; 36(7):508-14. PubMed ID: 23385474
[TBL] [Abstract][Full Text] [Related]
2. Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma.
Karavitaki N; Thanabalasingham G; Shore HC; Trifanescu R; Ansorge O; Meston N; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2006 Oct; 65(4):524-9. PubMed ID: 16984247
[TBL] [Abstract][Full Text] [Related]
3. Women with prolactinomas presented at the postmenopausal period.
Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
[TBL] [Abstract][Full Text] [Related]
4. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
5. Discrimination of prolactinoma from hyperprolactinemic non-functioning adenoma.
Hong JW; Lee MK; Kim SH; Lee EJ
Endocrine; 2010 Feb; 37(1):140-7. PubMed ID: 20963563
[TBL] [Abstract][Full Text] [Related]
6. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
7. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
[TBL] [Abstract][Full Text] [Related]
8. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
9. High prolactin level.
Piketty ML; Nataf F; Dilouya A; Roux FX
J Neurosurg; 2000 Feb; 92(2):368-9. PubMed ID: 10659034
[No Abstract] [Full Text] [Related]
10. In vivo imaging of pituitary tumours using a radiolabelled dopamine D2 receptor radioligand.
de Herder WW; Reijs AE; Kwekkeboom DJ; Hofland LJ; Nobels FR; Oei HY; Krenning EP; Lamberts SW
Clin Endocrinol (Oxf); 1996 Dec; 45(6):755-67. PubMed ID: 9039343
[TBL] [Abstract][Full Text] [Related]
11. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas.
St-Jean E; Blain F; Comtois R
Clin Endocrinol (Oxf); 1996 Mar; 44(3):305-9. PubMed ID: 8729527
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
13. PRL as a novel potent cofactor for platelet aggregation.
Wallaschofski H; Donné M; Eigenthaler M; Hentschel B; Faber R; Stepan H; Koksch M; Lohmann T
J Clin Endocrinol Metab; 2001 Dec; 86(12):5912-9. PubMed ID: 11739463
[TBL] [Abstract][Full Text] [Related]
14. Basal, pulsatile, entropic, and 24-hour rhythmic features of secondary hyperprolactinemia due to functional pituitary stalk disconnection mimic tumoral (primary) hyperprolactinemia.
Veldman RG; Frölich M; Pincus SM; Veldhuis JD; Roelfsema F
J Clin Endocrinol Metab; 2001 Apr; 86(4):1562-7. PubMed ID: 11297584
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients.
Primeau V; Raftopoulos C; Maiter D
Eur J Endocrinol; 2012 May; 166(5):779-86. PubMed ID: 22301915
[TBL] [Abstract][Full Text] [Related]
16. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
[TBL] [Abstract][Full Text] [Related]
17. Prolactinomas: evolution after menopause.
Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L
Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients.
Vilar L; Freitas MC; Naves LA; Casulari LA; Azevedo M; Montenegro R; Barros AI; Faria M; Nascimento GC; Lima JG; Nóbrega LH; Cruz TP; Mota A; Ramos A; Violante A; Lamounier Filho A; Gadelha MR; Czepielewski MA; Glezer A; Bronstein MD
J Endocrinol Invest; 2008 May; 31(5):436-44. PubMed ID: 18560262
[TBL] [Abstract][Full Text] [Related]
19. Reversible weight gain and prolactin levels--long-term follow-up in childhood.
Galluzzi F; Salti R; Stagi S; La Cauza F; Chiarelli F
J Pediatr Endocrinol Metab; 2005 Sep; 18(9):921-4. PubMed ID: 16279371
[TBL] [Abstract][Full Text] [Related]
20. A predictive algorithm for evaluating elevated serum prolactin in patients with a sellar mass.
Cheng JS; Salinas R; Molinaro A; Chang EF; Kunwar S; Blevins L; Aghi MK
J Clin Neurosci; 2015 Jan; 22(1):155-60. PubMed ID: 25481269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]